相关实验视频

Updated: Jun 5, 2025

Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs

Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs

Published on: May 15, 2019

临床试验剂CPI-613在多发性骨髓瘤中的功能和机制

Haiqin Wang¹, Yibin Zhang², Yu Jiang¹

¹Department of Hematology, the Second Xiangya Hospital, School of Life Sciences, Hunan Province Key Laboratory of Basic and Applied Hematology, Central South University, Changsha 410011, Hunan, China.

Biochemical pharmacology

|December 15, 2024

概括

针对线粒体新陈代谢的CPI-613抑制多发性髓瘤 (MM) 细胞生长和瘤进展. 将CPI-613与博尔特佐米布结合使用显示出增强的疗效,这表明其作为一种新型MM疗法的潜力.

科学领域:

在瘤学瘤学.
血液学血液学血液学
线粒体的新陈代谢

背景情况:

多发性骨髓瘤 (MM) 是一种无法治愈的血细胞恶性瘤,经常出现药物耐药性和复发.
目前的MM治疗改善了缓解,但没有提供治愈.
包括OGDH和PDHA1在内的TCA循环基因在MM中被确定为临床相关的.

研究的目的:

为了研究CPI-613的治疗潜力,一个线粒体抑制剂,在多发性骨髓瘤.
评估单独使用CPI-613和与博特佐米布 (BTZ) 结合使用的MM疗效.
在MM细胞和体内模型中阐明CPI-613的作用机制.

主要方法:

对TCA循环进行全面查,以确定MM中的关键基因.
在体外研究评估CPI-613对MM细胞增殖,线粒体功能和亡的影响.
使用老鼠异种移植模型进行体内研究,以评估瘤生长抑制和亡诱导.

主要成果:

CPI-613显示出显著抑制了MM细胞增殖.
与CPI-613和博特佐米布的联合治疗在较低剂量时显示出协同效应.
CPI-613破坏了线粒体形态,减少了氧化酸化,减少了ATP的产生,增加了ROS,导致了内在的亡.
在MM异种移植中,CPI-613显著抑制了瘤生长并诱导了亡.

结论:

通过线粒体功能障碍和诱导亡,CPI-613有效抑制多发性髓瘤细胞生长和瘤进展.
CPI-613,特别是与博尔特佐米布联合使用,代表了MM的有前途的治疗策略.
需要进一步的临床试验来证实CPI-613在MM治疗中的有效性和安全性.

关键词:

细胞灭亡 (apoptosis) 是一种死亡的过程.在CPI-61313指数下.线粒体中的线粒体.多发性骨髓瘤是一种多发性骨髓瘤.

更多相关视频

Isolation and Expansion of Cytotoxic Cytokine-induced Killer T Cells for Cancer Treatment

Isolation and Expansion of Cytotoxic Cytokine-induced Killer T Cells for Cancer Treatment

Published on: January 24, 2020

Repression of Multiple Myeloma Cell Growth In Vivo by Single-wall Carbon Nanotube SWCNT-delivered MALAT1 Antisense Oligos

Repression of Multiple Myeloma Cell Growth In Vivo by Single-wall Carbon Nanotube SWCNT-delivered MALAT1 Antisense Oligos

Published on: December 13, 2018

相关概念视频

Inhibition of Cdk Activity

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...

Combination Therapies and Personalized Medicine

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...